Companies › Tolmar
2 active drug programs in 3 registered trials: 1 Phase 3, 1 Phase 4, 1 Phase 2; Oncology, Metabolic and endocrine; next expected readout Jan 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Testosterone Undecanoate Androgen Receptor agonist | AR | Phase 4 | Hypogonadism; Prostate Cancer | – |
| TOL2506 GnRH receptor agonist for ovarian suppression | GNRH1 | Phase 3 | Breast Cancer | Jan 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06385509 | Testosterone Undecanoate | Phase 4 | Hypogonadism | Metabolic and endocrine | Nov 2025 |
| NCT05081193 | Testosterone Undecanoate | Phase 2 | Prostate Cancer | Oncology | Dec 2026 |
| NCT04906395 | TOL2506 | Phase 3 | Breast Cancer | Oncology | Jan 2027 |
Aragon Pharmaceuticals Acrotech Biopharma LaNova Medicines Zhejiang Quetzal Therapeutics Beijing Pearl Biotechnology Limited Liability Company
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.